Biofrontera Completes Phase 3 Trial for Ameluz PDT in Actinic Keratoses
ByAinvest
Tuesday, Sep 16, 2025 10:37 am ET1min read
BFRI--
Biofrontera Inc. has announced that the final patient has completed the active treatment phase of its Phase 3 clinical trial for Ameluz® PDT in actinic keratoses (AKs) on the extremities, neck, and trunk. All 172 enrolled patients have entered the 12-month follow-up phase, with study results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet